Claire Emson

Medicine · Health Sciences

30h-index4.6kcitations73works4.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Asthma and respiratory diseases(18), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis(10), Chronic Lymphocytic Leukemia Research(10), Pulmonary Hypertension Research and Treatments(7), Allergic Rhinitis and Sensitization(7)

Publications73 total

Claire's PhD Project
Deakin Research Online (Deakin University)·2026Open Access
Combined antagonism of Oncostatin M (OSM) and Interleukin 6 (IL-6) provides both anti-fibrotic and anti-inflammatory benefit in pulmonary fibrosis
2025Open Access
OP0058 DAZODALIBEP (ANTI-CD40L) EFFECTIVELY REDUCES MULTIPLE PROTEINS ASSOCIATED WITH B-, T-, AND DENDRITIC CELL BIOMARKERS IN SJÖGREN’S DISEASE: CORROBORATION OF IMMUNOPHENOTYPING FINDINGS FROM THE ALISS PHASE 2 STUDY
Annals of the Rheumatic Diseases·2024
AB0746 CD40L BLOCKADE WITH DAZODALIBEP SIGNIFICANTLY IMPROVES DISEASE ACTIVITY, SWOLLEN AND TENDER JOINT COUNTS, WHILE REDUCING MULTIPLE T- AND B-CELL BIOMARKERS IN THE MIDORA PHASE 2 STUDY OF PATIENTS WITH MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS
Annals of the Rheumatic Diseases·2024
Pharmacokinetics/pharmacodynamics of benralizumab in chronic rhinosinusitis with nasal polyps: Phase III, randomized, placebo‐controlled OSTRO trial
British Journal of Clinical Pharmacology·2024· 9 citedOpen Access
Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis
European Respiratory Review·2024· 15 citedOpen Access
Tezepelumab and Mucus Plugs in Patients with Moderate-to-Severe Asthma
NEJM Evidence·2023· 89 cited
Systemic Markers of Lung Function and Forced Expiratory Volume in 1 Second Decline across Diverse Cohorts
Annals of the American Thoracic Society·2023· 10 citedOpen Access
POS0815 CD40L BLOCKADE WITH DAZODALIBEP (VIB4920/HZN4920) REDUCES BLOOD BIOMARKERS OF T AND B CELL COSTIMULATION IN SUBJECTS WITH SYSTEMIC SJÖGREN’S SYNDROME
2023Open Access
LOXL4, but not LOXL2, is the critical determinant of pathological collagen cross-linking and fibrosis in the lung
Science Advances·2023· 44 citedOpen Access
A WISP1 antibody inhibits MRTF signaling to prevent the progression of established liver fibrosis
Cell Metabolism·2022· 46 cited
Feno differentiates epithelial gene expression clusters: Exploratory analysis from the MESOS randomized controlled trial
Journal of Allergy and Clinical Immunology·2022· 17 cited
Correction to: Intraclonal Complexity in Chronic Lymphocytic Leukemia: Fractions Enriched in Recently Born/Divided and Older/Quiescent Cells
Molecular Medicine·2022· 2 citedOpen Access
Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial
Journal of Allergy and Clinical Immunology·2021· 283 citedOpen Access
TGFβ2 and TGFβ3 isoforms drive fibrotic disease pathogenesis
Science Translational Medicine·2021· 125 citedOpen Access
Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial
The Lancet Respiratory Medicine·2021· 295 cited
Effect of Tezepelumab on Airway Inflammation in Patients with Moderate-to-Severe Uncontrolled Asthma: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study (CASCADE)
2021· 1 citedOpen Access
Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma with and without Nasal Polyposis: A Post Hoc Analysis of the Phase 2b PATHWAY Study
Journal of Asthma and Allergy·2021· 63 citedOpen Access
A WISP1 Antibody Inhibits MRTF Signaling to Prevent the Progression of Established Liver Fibrosis
SSRN Electronic Journal·2021Open Access
CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma
Respiratory Research·2020· 37 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Scott Turner(15), Marc K. Hellerstein(14), Kelvin W. Li(9), Nicholas Chiorazzi(7), Andrew N. J. McKenzie(6), Hans D. Brightbill(6), Gene Colice(5), Zhiyu Huang(5), Padraic G. Fallon(4), Sarah Diver(4), Jane R. Parnes(4), Christopher E. Brightling(4), René de Waal Malefyt(4), Jennifer Louten(4), Xiao‐Jie Yan(4), Gregory M. Hayes(4), Elizabeth J. Murphy(4), Michelle Gatmaitan(4), Patrick Caplazi(4), Surinder Jeet(4)